At a glance
Effects
- Neurogenesis: Promotes formation of new neurons, particularly in the hippocampus, by inhibiting LIF and stimulating BDNF — demonstrated in rodent models [1][3].
- Cognitive enhancement: Improves spatial memory and learning performance in Morris water-maze and other preclinical tasks; effects correlate with neuronal maturation timelines of 2–4 weeks [3].
- Neuroprotection: Shields neurons from oxidative stress, excitotoxicity, and inflammation; reduces tau and amyloid-beta pathology in Alzheimer's disease mouse models [1][6].
- Synaptic plasticity: Restores synaptic markers including synaptophysin and synapsin I in treated animals, supporting improved neurotransmitter release and connectivity [5].
- Appetite suppression (secondary): Proposed secondary effect via CNTF-pathway elevation of alpha-MSH; not a primary target and not confirmed in human data [7].
Synthetic nootropic tetrapeptide (CNTF-mimetic)
Preclinical only — no human trials completed
Intranasal (preferred) or subcutaneous injection
Cumulative over 2–4 weeks (neurogenic timeline)
C₂₄H₄₀N₈O₁₀ / MW 600.62 g/mol
About P21
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
P21 (also written P021) is a synthetic tetrapeptide derived from the biologically active region (amino acids 148–151) of ciliary neurotrophic factor (CNTF), classified as a research-stage nootropic neuropeptide [1]. It is investigated preclinically for cognitive enhancement, neuroprotection, and neurogenesis — with no approved human clinical use [2].
How it works
P21 works through several complementary pathways [1][3]. It inhibits leukemia inhibitory factor (LIF) signalling, removing a key brake on neurogenesis and shifting the brain toward a state favouring new neuron growth [1]. Simultaneously it upregulates BDNF (brain-derived neurotrophic factor), the brain's primary growth factor for neuron survival and synaptic plasticity [3]. It also partially activates the JAK/STAT pathway and upregulates CREB — the transcription factor that converts short-term neural activity into lasting structural change [4][5]. An adamantane modification on the glycine residue allows the peptide to cross the blood-brain barrier more effectively than native CNTF, which is too large to penetrate [6]. All established mechanistic data come from animal and in-vitro models; human pharmacodynamics remain unknown [2].
Risks & side effects
Most important: P21 has NO controlled human clinical trial data — every safety and efficacy finding comes from animal studies and cell culture experiments [2][8]. The long-term consequences of sustained BDNF-pathway modulation in humans are entirely unknown, meaning unforeseen neurological effects cannot be ruled out.
Common
- Injection-site reactions (redness, swelling, mild pain) with subcutaneous administration [9]
- Nasal irritation, stinging, or congestion with intranasal route [10]
- Transient mild headache in the first 1–2 weeks, attributed to rising BDNF levels [10]
- Initial fatigue as brain metabolic demands increase during active neurogenesis [10]
Serious
- Unknown long-term CNS consequences of sustained BDNF/LIF pathway modulation in humans — entirely unstudied [2][8]
- No safety data in pregnant or lactating individuals, or in those with pre-existing neurological or psychiatric conditions [2]
- Contamination or incorrect reconstitution of research-grade peptide vials poses infection and dosing-error risk [11]
Safety & harm reduction
- No validated human monitoring protocol exists; conservative practice recommends baseline cognitive assessment before use [2]
- Monitor injection or nasal-administration sites for persistent inflammation or infection [9]
- Observe for mood changes, unusual fatigue, or persistent headaches; discontinue if symptoms worsen beyond the first two weeks [10]
- No formal interaction studies have been conducted in humans [2]
- Theoretical additive neurogenic effect when stacked with other BDNF-modulating peptides (e.g. Dihexa, Semax) — combined safety is unstudied [12]
- Avoid combining with psychiatric medications (antidepressants, antipsychotics) without medical supervision given overlapping neurotrophic pathways [2]
- Use bacteriostatic water (BAC water) for reconstitution; maintain sterile technique throughout [11]
- Reconstituted solution should be crystal-clear — discard if cloudy or particulate matter is visible [11]
- Begin at lowest effective dose and increase only after 1–2 weeks of tolerance assessment [10]
- Cycle usage (4–8 weeks on, 2–4 weeks off) is the community convention; long-term continuous use has no safety evaluation [12]
- Store lyophilised powder away from light, heat, and temperature fluctuations; refrigerate reconstituted solution [13]
- Source only third-party-tested, purity-verified product given research-only classification [11]
Dosage context
All dosing is community-reported and derived from allometric scaling of animal studies — NOT a medical prescription. Commonly reported intranasal range: 500 mcg–2 mg once daily, with some sources citing increases to 2–4 mg for more acute effects [14][15]. Subcutaneous dosing is reported in the same 500 mcg–2 mg daily range [12]. Typical cycle length: 4–8 weeks [12]. Neurogenic effects are cumulative and not expected to be felt acutely — allow 2–4 weeks minimum before assessing response [10]. Higher doses (above ~1.0 mg/kg in animal models) show diminishing returns rather than escalating toxicity [16]. No human-validated therapeutic dose exists.
Sources
- 1.Peptide-DB — P21 Overview
- 2.Peptide Initiative — P21 Safety & Dosing
- 3.SeekPeptides — P21 Benefits Guide
- 4.PeptideDeck — P21 Research Guide
- 5.Peptide Biologix — P21 Molecular Monograph
- 6.International Peptide Society — P21 Monograph
- 7.Core Peptides — P21 in Neurological Disorders
- 8.Real Peptides — Is P21 Safe?
- 9.PepDose — P21 Side Effects
- 10.Peptide Initiative — P21 Protocol
- 11.Pep-Pedia — P21 Dosing & Safety
- 12.PeptideDeck — Adamax/P21 Stack Guide
- 13.Direct Peptides — P21 Nootropic
- 14.Jay Campbell — Adamax & P21 Nootropics
- 15.Peptide Patterns — P21 Dosage Guide
- 16.Real Peptides — P21 Mechanism Detailed
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.